9903327-6.
1998 COM

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/10, 15/70 — A2

(11) International Publication Number: **WO 98/33901**

(43) International Publication Date: 6 August 1998 (06.08.98)

(21) International Application Number: PCT/EP98/00533

(22) International Filing Date: 2 February 1998 (02.02.98)

(30) Priority Data:
97101539.1 31 January 1997 (31.01.97) EP
(34) Countries for which the regional or international application was filed: DE et al.

(71) Applicant *(for all designated States except US)*: COSMIX MOLECULAR BIOLOGICALS GMBH [DE/DE]; Mascheroder Weg 1, D–38124 Braunschweig (DE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: COLLINS, John [GB/DE]; Aegidienstrasse 5, D–38100 Braunschweig (DE). RÖTTGEN, Peter [DE/DE]; Mascheroder Weg 1, D–38124 Braunschweig (DE).

(74) Agents: BOETERS, Hans, D. et al.; Boeters & Bauer, Bereiteranger 15, D–81541 München (DE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: GENERATION OF DIVERSITY IN COMBINATORIAL LIBRARIES

(57) Abstract

The invention concerns gene banks and combinatorial derivatives thereof, prepared using phagemid– or phage–display in combination with type IIS restriction enzymes and cosmid packaging; their use for the isolation of ligands, including enzyme inhibitors, agonists and antagonists for receptors, competitive binding peptides to a defined target, diagnostic ligands for diseases and autoimmune syndromes, including surveillance tools for immune status, post–translationally modified peptides, and such ligands generated by this technology.